These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 33892317

  • 1. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
    Selmaj KW, Cohen JA, Comi G, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Havrdova EK, Cree BAC, Minton N, Sheffield JK, Ding N, Kappos L.
    Mult Scler Relat Disord; 2021 Jun; 51():102844. PubMed ID: 33892317
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators.
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW, RADIANCE Study Group.
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Kappos L, Cohen JA.
    Mult Scler; 2022 Oct; 28(12):1944-1962. PubMed ID: 35765217
    [Abstract] [Full Text] [Related]

  • 6. Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS.
    DeLuca J, Schippling S, Montalban X, Kappos L, Cree BAC, Comi G, Arnold DL, Hartung HP, Sheffield JK, Liu H, Silva D, Cohen JA.
    Mult Scler Relat Disord; 2021 Feb; 48():102673. PubMed ID: 33454584
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L, RADIANCE Trial Investigators.
    Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
    [Abstract] [Full Text] [Related]

  • 8. Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis.
    Nie T, Syed YY.
    CNS Drugs; 2024 Nov; 38(11):931-941. PubMed ID: 39368032
    [Abstract] [Full Text] [Related]

  • 9. Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Sun Y, Yang Y, Wang Z, Jiang F, Chen Z, Wang Z.
    Front Pharmacol; 2020 Nov; 11():589146. PubMed ID: 33658933
    [Abstract] [Full Text] [Related]

  • 10. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S, Kumar J, Arndorfer S, Zhu X, Zivkovic M, Tencer T.
    CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
    [Abstract] [Full Text] [Related]

  • 11. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L, Paul F.
    Expert Opin Pharmacother; 2018 Dec; 19(18):2073-2086. PubMed ID: 30407868
    [Abstract] [Full Text] [Related]

  • 12. Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial.
    Naismith RT, Cohen JA, Bar-Or A, Comi G, Selmaj KW, Hartung HP, Sheffield JK, Krakovich A, Tatosian D, Cheng CY, Reardon J, Khaychuk V, Riolo JV, Silva D, Cree BA.
    Mult Scler; 2024 Feb; 30(2):177-183. PubMed ID: 38130041
    [Abstract] [Full Text] [Related]

  • 13. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
    Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J.
    J Comp Eff Res; 2020 Mar; 9(4):275-285. PubMed ID: 31948278
    [Abstract] [Full Text] [Related]

  • 14. Ozanimod: First Approval.
    Lamb YN.
    Drugs; 2020 Jun; 80(8):841-848. PubMed ID: 32385738
    [Abstract] [Full Text] [Related]

  • 15. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials.
    Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, Southworth H, Kappos L, Cohen JA, Ozanimod Study Investigators.
    Eur J Neurol; 2021 Nov; 28(11):3722-3730. PubMed ID: 34292643
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.
    Armuzzi A, Cross RK, Lichtenstein GR, Hou J, Deepak P, Regueiro M, Wolf DC, Akukwe L, Ahmad HA, Jain A, Kozinn M, Wu H, Petersen A, Charles L, Long M.
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1067-1076.e3. PubMed ID: 38040274
    [Abstract] [Full Text] [Related]

  • 17. Ozanimod for the treatment of relapsing forms of multiple sclerosis.
    Kuczynski AM, Oh J.
    Neurodegener Dis Manag; 2021 Jun; 11(3):207-220. PubMed ID: 34011158
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.
    Danese S, Panaccione R, Abreu MT, Rubin DT, Ghosh S, Dignass A, Afzali A, Wolf DC, Chiorean MV, Vermeire S, Jain A, Charles L, Lawlor G, Osterman MT, Wu H, Canavan JB, Petersen A, Colombel JF, Regueiro M.
    J Crohns Colitis; 2024 Feb 26; 18(2):264-274. PubMed ID: 37651686
    [Abstract] [Full Text] [Related]

  • 19. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program.
    Feagan BG, Schreiber S, Afzali A, Rieder F, Hyams J, Kollengode K, Pearlman J, Son V, Marta C, Wolf DC, D'Haens GG.
    Contemp Clin Trials; 2022 Nov 26; 122():106958. PubMed ID: 36208720
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison.
    Swallow E, Pham T, Patterson-Lomba O, Yin L, Gomez-Lievano A, Liu J, Tencer T, Gupte-Singh K.
    Mult Scler Relat Disord; 2023 Mar 26; 71():104551. PubMed ID: 36791623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.